Search alternatives:
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
ng decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
n decrease » _ decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
50 nn » 50 ns (Expand Search), 50 ng (Expand Search), 59 nn (Expand Search)
50 n » 50 ns (Expand Search), 50 ng (Expand Search), 50 μ (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
ng decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
n decrease » _ decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
50 nn » 50 ns (Expand Search), 50 ng (Expand Search), 59 nn (Expand Search)
50 n » 50 ns (Expand Search), 50 ng (Expand Search), 50 μ (Expand Search)
-
141
-
142
Identification, Synthesis, and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine Methyltransferases
Published 2022“…CARM1 (coactivator-associated arginine methyltransferase 1), which belongs to type I PRMTs (protein arginine methyltransferases), is a potential therapeutic target for treatment of multiple cancers. In this study, we first identified several hit compounds against CARM1 by structure-based virtual screening (IC<sub>50</sub> = 35.51 ± 6.68 to 68.70 ± 8.12 μM) and then carried out chemical structural optimizations, leading to six compounds with significantly improved activities targeting CARM1 (IC<sub>50</sub> = 18 ± 2 to 107 ± 6 nM). …”
-
143
Variable included in analysis.
Published 2025“…</p><p>Results</p><p>Our final study sample consisted of 3 256 clients, half of which received case management (N = 1 628), 1084 (33%) with a first VL in study of 50–399 copies/ml, 404 (12%) 400–999 copies/ml and 1768 (54%) >1000 copies/ml. …”
-
144
Full dataset of the study.
Published 2025“…</p><p>Results</p><p>Our final study sample consisted of 3 256 clients, half of which received case management (N = 1 628), 1084 (33%) with a first VL in study of 50–399 copies/ml, 404 (12%) 400–999 copies/ml and 1768 (54%) >1000 copies/ml. …”
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
Data Sheet 1_Reduced hemolytic complement activity in the classical pathway (CH50) is a risk factor for poor clinical outcomes of patients with infections: a retrospective analysis...
Published 2025“…We divided the patients into three groups based on the normal CH50 range: Low CH50 (< 25 U/mL; n=168), Normal CH50 (25 ≤, < 48 U/mL; n=1273), and High CH50 (48 ≤ U/mL; n=1285).…”
-
157
Top 50 results of a commercial kinase screen using [γ<sup>33</sup>]-ATP and human obscurin SH3-DH as substrates.
Published 2023“…While MST2 addition resulted in strong and saturable phosphorylation, TBK1 led to much lower phosphorylation levels and CaMK4 addition led to an intermediate phosphorylation level exhibiting a biphasic behaviour with phosphorylation levels decreasing at higher substrate concentrations. Since MST2 showed the highest phosphorylation levels of obscurin SH3-DH, we focused on MST2 phosphorylation in all further experiments. …”
-
158
-
159
-
160